Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFGYZ8)

Drug Name
AR882 Drug Info
Indication
Disease Entry ICD 11 Status REF
Gout FA25 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMFGYZ8

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Urate anion exchanger 1 (URAT1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lesinurad DMUR64T Hyperuricaemia 5C55.Y Approved [3]
Dotinurad DM0UPQJ Gout FA25 Phase 3 [4]
URC102 DMY89BN Gout FA25 Phase 2 [5]
RDEA-684 DMNWYHD Gout FA25 Phase 2 [3]
RDEA3170 DM1TKG4 Hyperuricaemia 5C55.Y Phase 2 [6]
Sulfonamide derivative 11 DMJBR86 N. A. N. A. Patented [7]
Cycloalkyl acid derivative 1 DMXMGSP N. A. N. A. Patented [7]
2-ethyl-3-(4-hydroxy) benzoyl benzofuran derivative 1 DMHYIAV N. A. N. A. Patented [7]
Tihoacetate derivative 1 DM6QHO0 N. A. N. A. Patented [7]
Cycloalkyl acid derivative 2 DM09LY3 N. A. N. A. Patented [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Urate anion exchanger 1 (URAT1) TTA592U S22AC_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT04155918) A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of AR882 Administered Alone or in Combination With Febuxostat or Allopurinol in Gout Patients. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Arthrosi Therapeutics
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1031).
4 Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout. Expert Opin Pharmacother. 2021 Aug;22(11):1397-1406.
5 Clinical pipeline report, company report or official report of Chugai Pharmaceutical (2013).
6 The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. BMC Nephrol. 2013; 14: 164.
7 Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10.